Method of determining cytokine dosage for improving myelosuppressive state

• US 7,465,551 B2
• Filed: 08/07/2006
• Issued: 12/16/2008
• Est. Priority Date: 01/29/1999
• Status: Expired due to Fees

• Current Assignee: Center For Molecular Medicine and Immunology
• Original Assignee: Center For Molecular Medicine and Immunology
• Inventors: Goldenberg, David M., Blumenthal, Rosalyn D.
• Primary Examiner(s): MERTZ, PREMA MARIA
• Application Number:
  US11/500,186
• Publication Number:
  US 20070036749A1
• Time in Patent Office: 862 Days
• Field of Search: None
• US Class Current: 435/7.1
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 2333/475 Assays involving growth factors
• CPC Class Codes: G01N 2800/24 Immunology or allergic disorders SLE G01N2800/104
• CPC Class Codes: G01N 33/57488 involving compounds identifable in body fluids
• CPC Class Codes: G01N 33/6863 Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors

Abstract

The invention provides kits and methods for evaluating the myelosuppressive state of a patient. These methods and kits provide a useful adjunct for cytotoxic and myelosuppressive therapies. By establishing threshold levels of certain cytokines as a surrogate for myelosuppression, treatment protocols can be optimized to reduce myelotoxicity, while maximizing effective dose. Measured levels of one or more cytokines in a patient subjected to cytotoxic therapy, relative to a normal population, may be used to determine the dose of a hematopoietic cytokine to be administered to the patient.

Claims

1. A method of determining a dose of G-CSF to be administered to a patient before or after a myelosuppressive agent is to be administered to the patient, comprising:

(a) measuring a level of G-CSF in a sample from the patient;

(b) comparing the level of G-CSF measured in the sample to levels of G-CSF in normal subjects;

(c) determining the dose of G-CSF to be administered to the patient based on the comparison of G-CSF levels; and

(d) administering the dose of G-CSF to the patient.

2. The method of claim 1 wherein the level of G-CSF is measured in the patient before administering the myelosuppressive agent to the patient.

3. The method of claim 1 wherein the level of G-CSF is measured in the patient after administering the myelosuppressive agent to the patient.

4. The method of claim 1 wherein the level of G-CSF is measured in the patient before and after administering the myelosuppressive agent to the patient.

5. The method of claim 1 further comprising measuring levels of at least one other hematopoietic cytokine selected from the group consisting of SCE, ELT-3L, JL-1, IL-3, IL-11, MIP-1α

, TGF-γ

3 and TNF-α

in the sample.